Fortification and supplementation effect on vitamin D levels

Phase 3

Conditions: Healthy people.

Registration Number: IRCT20180708040401N1

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 99

Inclusion Criteria

18-30 years old
The absence of diseases which influence the metabolism of Ca, P and vitamin D such as thyroid and parathyroid disorders, chronic kidney disease, osteoporosis, or bone fractures caused by osteoporosis, during the past year
The absence of cardiovascular disease, diabetes, chronic digestive diseases, hepatitis and cancer
No medical treatment for osteoporosis or other bone diseases in the last 6 months, such as taking Bisphosphonates, Raloxifene, Teriparatide and Denosambe
Not using Glucocorticoids
Not using nutritional supplements
No pregnancy and lactation
Not participating in other studies in the last 6 months

Exclusion Criteria

The presence of diseases affecting the metabolism of phosphorus, calcium and vitamin D
The presence of cardiovascular disease, diabetes, chronic diseases of the digestive tract, hepatitis and cancer
Medical treatment for osteoporosis or other bone diseases in the last 6 months
Treatment with glucocorticoids
Using nutritional supplements
Pregnancy and lactating
Participating in other studies in the last 6 months

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
25-hydroxy vitamin D. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Parathyroid hormone. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Bone specific alkalin phosphatase. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Spectophotometric assay.;Collagen type 1 cross-linked C-telopeptide I(CTX-I). Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).

Secondary Outcome Measures